Laboratory revenue cycle management encompasses every operational process connecting clinical laboratory services to collected Medicare reimbursement – and in August 2026, it has become the most actionable lever available to laboratory executives preparing for a confirmed payment shift. The Consolidated Appropriations Act, 2026, signed February 3, 2026, delayed all PAMA-related Clinical Laboratory Fee Schedule (CLFS) rate reductions through December 31, 2026 – the seventh Congressional intervention since PAMA was enacted [1]. But the reprieve is temporary.

Most healthcare organizations don't decide to outsource medical billing because of a single crisis. The decision builds ...
read more
FQHC revenue cycle management can be complex and resource-intensive. Outsourcing revenue cycle management in FQHCs (fede...
read more